CureVac N.V.

14.62-0.3100-2.08%Vol 2.90M1Y Perf -75.02%
Jun 24th, 2022 16:00 DELAYED
BID14.41 ASK15.39
Open15.09 Previous Close14.93
Pre-Market- After-Market14.50
 - -  -0.12 -0.82%
Target Price
28.67 
Analyst Rating
Hold 2.67
Potential %
96.10 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     47.43
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     58.21
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.72 
Earnings Rating
Market Cap2.74B 
Earnings Date
28th Jul 2022
Alpha-0.04 Standard Deviation0.34
Beta3.51 

Today's Price Range

14.5815.36

52W Range

12.9076.22

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
2.45%
1 Month
-16.50%
3 Months
-22.32%
6 Months
-60.27%
1 Year
-75.02%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CVAC14.62-0.3100-2.08
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date28th Jul 2022
Estimated EPS Next Report-0.85
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume2.90M
Shares Outstanding187.12K
Shares Float72.07M
Trades Count9.57K
Dollar Volume42.69M
Avg. Volume616.88K
Avg. Weekly Volume649.96K
Avg. Monthly Volume636.02K
Avg. Quarterly Volume564.65K

CureVac N.V. (NASDAQ: CVAC) stock closed at 14.62 per share at the end of the most recent trading day (a -2.08% change compared to the prior day closing price) with a volume of 2.90M shares and market capitalization of 2.74B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 484 people. CureVac N.V. CEO is Franz-Werner Haas.

The one-year performance of CureVac N.V. stock is -75.02%, while year-to-date (YTD) performance is -57.39%. CVAC stock has a five-year performance of %. Its 52-week range is between 12.9 and 76.22, which gives CVAC stock a 52-week price range ratio of 2.72%

CureVac N.V. currently has a PE ratio of -7.60, a price-to-book (PB) ratio of 3.78, a price-to-sale (PS) ratio of 20.17, a price to cashflow ratio of 9.20, a PEG ratio of 2.32, a ROA of -30.50%, a ROC of -43.24% and a ROE of -46.40%. The company’s profit margin is -%, its EBITDA margin is -242.90%, and its revenue ttm is $132.37 Million , which makes it $0.71 revenue per share.

Of the last four earnings reports from CureVac N.V., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.85 for the next earnings report. CureVac N.V.’s next earnings report date is 28th Jul 2022.

The consensus rating of Wall Street analysts for CureVac N.V. is Hold (2.67), with a target price of $28.67, which is +96.10% compared to the current price. The earnings rating for CureVac N.V. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CureVac N.V. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CureVac N.V. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.39, ATR14 : 1.06, CCI20 : -38.67, Chaikin Money Flow : -0.27, MACD : -0.85, Money Flow Index : 54.04, ROC : -11.50, RSI : 42.75, STOCH (14,3) : 33.46, STOCH RSI : 0.86, UO : 45.26, Williams %R : -66.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CureVac N.V. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
1 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
2 (50.00 %)
Moderate Sell
1 (33.33 %)
1 (33.33 %)
1 (25.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
2.67
Hold
2.67
Hold
2.75

CureVac N.V.

CureVac NV a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.

CEO: Franz-Werner Haas

Telephone: +49 707198830

Address: Friedrich-Miescher-Strasse 15, Tubingen 72076, BW, DE

Number of employees: 484

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

TipRanks News for CVAC

Thu, 10 Feb 2022 19:35 GMT CureVac (CVAC) Gets a Buy Rating from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits